Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress
– Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 –
Covered in this story
Call it yourself
No calls on $ABEO yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Abeona Therapeutics Inc →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.